Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Buisson

Showing results (111-120 of 166) with videos related to

Pageof 17
Sort By:
Frontiers in Immunology|November 21, 2022
Relationships of circulating CD4<sup>+</sup> T cell subsets and cytokines with the risk of relapse in patients with Crohn's diseaseRémi Duclaux-Loras, Gilles Boschetti, Bernard Flourie, et al.
Therapeutic Advances in Gastroenterology|August 9, 2024
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAIDBénédicte Caron, Philippe Seksik, Anthony Buisson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 29, 2024
Early Biological Therapy Within 12 Months of Diagnosis Leads to Higher Transmural Healing Rates in Crohn's DiseaseJoana Revés, Agnes Fernandez-Clotet, Ingrid Ordás, et al.
The American Journal of Gastroenterology|August 16, 2022
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAIDGilles Boschetti, Maria Nachury, David Laharie, et al.
Gut|June 5, 2025
Adherent-invasive <i>Escherichia coli</i> in Crohn's disease: the 25th anniversaryNicolas Barnich, Janelle C Arthur, Anthony Buisson, et al.
United European Gastroenterology Journal|November 18, 2021
Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn's diseaseAnthony Buisson, Emilie Vazeille, Mathurin Fumery, et al.
Journal of Crohn'S & Colitis|January 14, 2020
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort StudyAntoine Martin, Maria Nachury, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|February 26, 2022
Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective CohortClément Julien, Emré Anakok, Xavier Treton, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative ColitisMathieu Uzzan, Julien Kirchgesner, Nadia Oubaya, et al.
Pageof 17

Showing results (111-120 of 166) with videos related to

Sort By:
Pageof 17
Frontiers in Immunology|November 21, 2022
Relationships of circulating CD4<sup>+</sup> T cell subsets and cytokines with the risk of relapse in patients with Crohn's diseaseRémi Duclaux-Loras, Gilles Boschetti, Bernard Flourie, et al.
Therapeutic Advances in Gastroenterology|August 9, 2024
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAIDBénédicte Caron, Philippe Seksik, Anthony Buisson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 29, 2024
Early Biological Therapy Within 12 Months of Diagnosis Leads to Higher Transmural Healing Rates in Crohn's DiseaseJoana Revés, Agnes Fernandez-Clotet, Ingrid Ordás, et al.
The American Journal of Gastroenterology|August 16, 2022
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAIDGilles Boschetti, Maria Nachury, David Laharie, et al.
Gut|June 5, 2025
Adherent-invasive <i>Escherichia coli</i> in Crohn's disease: the 25th anniversaryNicolas Barnich, Janelle C Arthur, Anthony Buisson, et al.
United European Gastroenterology Journal|November 18, 2021
Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn's diseaseAnthony Buisson, Emilie Vazeille, Mathurin Fumery, et al.
Journal of Crohn'S & Colitis|January 14, 2020
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort StudyAntoine Martin, Maria Nachury, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|February 26, 2022
Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective CohortClément Julien, Emré Anakok, Xavier Treton, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative ColitisMathieu Uzzan, Julien Kirchgesner, Nadia Oubaya, et al.
Pageof 17